Citius Pharmaceuticals Inc (NASDAQ:CTXR) — Market Cap & Net Worth
Market Cap & Net Worth: Citius Pharmaceuticals Inc (CTXR)
Citius Pharmaceuticals Inc (NASDAQ:CTXR) has a market capitalization of $15.66 Million ($15.66 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25727 globally and #5172 in its home market, demonstrating a -24.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Citius Pharmaceuticals Inc's stock price $0.70 by its total outstanding shares 22376427 (22.38 Million). Analyse CTXR cash flow metrics to see how efficiently the company converts income to cash.
Citius Pharmaceuticals Inc Market Cap History: 2015 to 2026
Citius Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $15.52 Billion to $15.66 Million (-46.26% CAGR).
Index Memberships
Citius Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #737 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2429 of 3165 |
Weight: Citius Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Citius Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Citius Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CTXR by Market Capitalization
Companies near Citius Pharmaceuticals Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Citius Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Citius Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Citius Pharmaceuticals Inc's market cap moved from $15.52 Billion to $ 15.66 Million, with a yearly change of -46.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $15.66 Million | -9.91% |
| 2025 | $17.39 Million | -80.58% |
| 2024 | $89.51 Million | -78.85% |
| 2023 | $423.19 Million | -4.24% |
| 2022 | $441.93 Million | -48.70% |
| 2021 | $861.49 Million | +50.98% |
| 2020 | $570.60 Million | 0.00% |
| 2019 | $570.60 Million | -1.92% |
| 2018 | $581.79 Million | -72.63% |
| 2017 | $2.13 Billion | -42.95% |
| 2016 | $3.73 Billion | -76.00% |
| 2015 | $15.52 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Citius Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.66 Million USD |
| MoneyControl | $15.66 Million USD |
| MarketWatch | $15.66 Million USD |
| marketcap.company | $15.66 Million USD |
| Reuters | $15.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more